BAUSCH HEALTH AMERICAS, INC.
- Country
- ๐บ๐ธUnited States
- Ownership
- Subsidiary
- Employees
- 3.1K
- Market Cap
- -
- Website
- http://www.bauschhealth.com
Long-Term Safety and Tolerability of Mesalamine Pellets in Participants With Ulcerative Colitis in Remission
- Conditions
- Interventions
- First Posted Date
- 2006-05-16
- Last Posted Date
- 2019-11-01
- Lead Sponsor
- Bausch Health Americas, Inc.
- Target Recruit Count
- 393
- Registration Number
- NCT00326209
- Locations
- ๐บ๐ธ
Little Rock Diagnostic Clinic, Little Rock, Arkansas, United States
๐บ๐ธAGMG Clinical Research, Anaheim, California, United States
๐บ๐ธLovelace Scientific Resources, Sarasota, Florida, United States
A Study Comparing the Effectiveness and Safety of Varying Dose Strengths (100, 200, 300 and 400 mg) of Extended-release Tramadol HCl With Placebo for the Treatment of Osteoarthritis(OA) of the Knee and/or Hip
- Conditions
- First Posted Date
- 2006-05-15
- Last Posted Date
- 2012-08-27
- Lead Sponsor
- Bausch Health Americas, Inc.
- Target Recruit Count
- 1000
- Registration Number
- NCT00325858
- Locations
- ๐บ๐ธ
Altoona Center for Clinical Research, Duncansville, Pennsylvania, United States
Study Evaluating the Safety of MOA-728 Administered Orally to Healthy Subjects
- Conditions
- First Posted Date
- 2006-04-05
- Last Posted Date
- 2019-11-25
- Lead Sponsor
- Bausch Health Americas, Inc.
- Target Recruit Count
- 48
- Registration Number
- NCT00311350
Viral Kinetic Study With Viramidine in Therapy-Naive Patients With Chronic Hepatitis C
- Conditions
- First Posted Date
- 2006-03-21
- Last Posted Date
- 2012-06-22
- Lead Sponsor
- Bausch Health Americas, Inc.
- Target Recruit Count
- 100
- Registration Number
- NCT00305383
- Locations
- ๐บ๐ธ
Maryland Digestive Disease Research, Laurel, Maryland, United States
๐บ๐ธSan Mateo Medical Center, San Mateo, California, United States
๐บ๐ธLiver Center of Long Island, Plainview, New York, United States
A 6-month Efficacy, Safety, and Tolerability Study of Rifaximin In Preventing Hepatic Encephalopathy
- First Posted Date
- 2006-03-01
- Last Posted Date
- 2019-09-18
- Lead Sponsor
- Bausch Health Americas, Inc.
- Target Recruit Count
- 299
- Registration Number
- NCT00298038
New Tablet Formulation and Dosing Regimen of Balsalazide Disodium in Mildly to Moderately Active Ulcerative Colitis
- Conditions
- First Posted Date
- 2005-12-23
- Last Posted Date
- 2019-11-25
- Lead Sponsor
- Bausch Health Americas, Inc.
- Target Recruit Count
- 225
- Registration Number
- NCT00269438
- Locations
- ๐บ๐ธ
VA Medical Center, Syracuse, New York, United States
๐บ๐ธNationsMed Clinical Research, Houston, Texas, United States
๐บ๐ธDigestive Health Center of Louisiana, Baton Rouge, Louisiana, United States
A Trial to Compare Xifaxan to Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD)
- Conditions
- Interventions
- First Posted Date
- 2005-12-23
- Last Posted Date
- 2019-10-14
- Lead Sponsor
- Bausch Health Americas, Inc.
- Target Recruit Count
- 237
- Registration Number
- NCT00269399
- Locations
- ๐บ๐ธ
Newland Medical Association, Southfield, Michigan, United States
๐บ๐ธUniversity of Maryland, Baltimore, Maryland, United States
๐บ๐ธDigestive Health Specialists, PA, Tupelo, Mississippi, United States
Study to Assess the Efficacy and Safety of Rifaximin Administered BID in the Treatment of Patients With Diarrhea-Associated Irritable Bowel Syndrome
- Conditions
- First Posted Date
- 2005-12-23
- Last Posted Date
- 2019-11-25
- Lead Sponsor
- Bausch Health Americas, Inc.
- Target Recruit Count
- 525
- Registration Number
- NCT00269412
- Locations
- ๐บ๐ธ
Gastroenterology Associates of Fairfield County, Bridgeport, Connecticut, United States
๐บ๐ธLitchfield County Gastroenterology Associates, LLC, Torrington, Connecticut, United States
๐บ๐ธUniversity Clinical Research, DeLand, Florida, United States
Study of Viramidine to Ribavirin in Patients With Chronic Hepatitis C Who Are Treatment-Naive
- Conditions
- First Posted Date
- 2005-10-03
- Last Posted Date
- 2012-06-22
- Lead Sponsor
- Bausch Health Americas, Inc.
- Target Recruit Count
- 900
- Registration Number
- NCT00230958
Dose-Ranging Study of Pradefovir in Patients With Compensated Hepatitis B
- Conditions
- First Posted Date
- 2005-09-30
- Last Posted Date
- 2012-06-22
- Lead Sponsor
- Bausch Health Americas, Inc.
- Target Recruit Count
- 220
- Registration Number
- NCT00230503